Mystic Asset Management Inc. Makes New $278,000 Investment in Hologic, Inc. (NASDAQ:HOLX)

Mystic Asset Management Inc. bought a new stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 4,500 shares of the medical equipment provider's stock, valued at approximately $278,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Allworth Financial LP lifted its holdings in shares of Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after acquiring an additional 216 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 260 shares during the last quarter. Larson Financial Group LLC raised its holdings in shares of Hologic by 6,016.7% during the 1st quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock valued at $45,000 after buying an additional 722 shares in the last quarter. Raiffeisen Bank International AG purchased a new position in shares of Hologic during the fourth quarter worth approximately $49,000. Finally, West Financial Advisors LLC purchased a new stake in shares of Hologic in the 1st quarter valued at $50,000. 94.73% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Morgan Stanley lowered their price objective on Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research report on Monday, May 5th. Raymond James Financial reissued an "outperform" rating and issued a $71.00 price target (down previously from $90.00) on shares of Hologic in a report on Friday, May 2nd. Stephens dropped their target price on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th. Mizuho raised their target price on Hologic from $65.00 to $70.00 and gave the stock an "outperform" rating in a research note on Wednesday. Finally, Evercore ISI upped their price target on Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research report on Tuesday, July 8th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Hologic presently has an average rating of "Hold" and an average price target of $77.33.

Hologic Price Performance

Shares of HOLX stock traded down $0.03 during trading hours on Friday, hitting $63.99. The stock had a trading volume of 1,582,099 shares, compared to its average volume of 2,386,077. The stock's 50-day moving average price is $62.46 and its two-hundred day moving average price is $63.18. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.67. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.24 and a quick ratio of 2.52. The stock has a market capitalization of $14.26 billion, a price-to-earnings ratio of 27.00, a PEG ratio of 2.35 and a beta of 0.55.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the company earned $1.03 earnings per share. The business's revenue for the quarter was down 1.2% compared to the same quarter last year. Equities analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Activity at Hologic

In other Hologic news, Director Martin D. Madaus purchased 5,445 shares of the company's stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the purchase, the director owned 5,445 shares of the company's stock, valued at approximately $300,781.80. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.88% of the stock is currently owned by company insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.